KN 510
Alternative Names: KN0-510; KN510Latest Information Update: 15 Feb 2024
At a glance
- Originator New Cancer Cure-Bio
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 11 Sep 2023 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in South Korea (PO) (NCT06012708)
- 28 Aug 2023 New Cancer Cure-Bio plans phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy, Inoperable) in September 2023 (PO) (NCT06012708)
- 28 Aug 2023 Preclinical trials in Solid tumours in South Korea (PO), before September 2023